FDA Approves Repotrectinib for ROS1-Positive NSCLC

The next-generation tyrosine kinase inhibitor provides a new treatment option for patients with this difficult-to-treat form of lung cancer.

Related Keywords

United States ,Jessicaj Lin , ,Bristol Myers Squibb ,Drug Administration ,Bristol Myers ,Lung Cancer ,Ung Carcinoma ,Ancer Lung ,Non Small Cell Lung Cancer ,Nsclc ,Biologic Therapy ,Small Cell Lung Cancer ,Lung ,Dentistry ,Otolaryngology ,Nt Ears ,Nose ,Throat ,Tyrosine Kinase Inhibitor ,Rlotinib ,Efitinib ,Matinib ,U11248 ,Unitinib ,Cancer ,Alignant Neoplasia ,Arcinoma ,Pneumonia ,Tyrosine Kinase ,Dyspnea ,Hypoxia ,Aspiration Pneumonia ,Peripheral Neuropathy ,Alabama ,Aspiration ,Ataxia ,